Intravenous Administration Of Endometrial Regenerative Cells (ERC) Induces Benefit In Heart Failure Patient

Medistem Inc. (PINKSHEETS: MEDS) reported today a recent publication in the peer reviewed journal International Archives of Medicine describing a 74 year old heart failure patient treated with the company's endometrial regenerative cell (ERC) product in November 2007. The patient's ejection fraction, meaning the heart's pumping activity, increased from 25-30% pre-treatment to 40% in June of 2008... http://mnt.to/f/3BtY